Jul. 16 at 4:14 PM
$JNJ’s Spravato continues to gain momentum as interest in psychedelic-based depression treatments grows.
While competitors like Compass Pathways’
$CMPS COMP360 are advancing in the space, analysts believe they are unlikely to create an immediate threat to Spravato’s current sales trajectory.
The bigger picture is that the depression treatment market is expanding, but adoption, regulatory approval, and real-world delivery will determine how quickly next-generation therapies can challenge established players.
